ICBR to Lead Kerafast Reagent Access Program at UF
The University of Florida has partnered with Kerafast, a reagent company looking to advance life science research by facilitating access to a variety of biological reagents from leading laboratories around the world. Kerafast operates an online platform that allows for a quick, one-click MTA and provides rapid access to unique and difficult-to-find reagents, helping remove traditional barriers to transferring biomaterials. “Our mission is to help mobilize these reagents globally and, into the hands of scientists that can benefit from them most, “says Amelia Gibson, Director of Business Development for Kerafast, “we are happy to invest our time and resources in promoting these materials and helping them find customer.”
Providers add their own reagents to the portfolio, where these materials can be easily accessed by other researchers. The company returns a generous portion of every sale to the contributing scientists and their institutions.
ICBR will be leading the UF Kerafast partnership by contributing high quality reagents from their diverse antibody collection and offering opt-in option for interested investigators. Researchers requesting new antibody generation from the ICBR Monoclonal antibody core will have an opportunity to join this program and have their monoclonal antibodies produced in the ICBR included in the Kerafast collection, in exchange for a portion of proceeds. We will be glad to help our customers from previous years participate but will need to verify whether their antibodies and associated reagents can be included.
All materials sold through Kerafast are offered through a non-exclusive license agreement. This allows participating investigators to share their research tools through traditional Material Transfer Agreement as well as take advantage of Kerafast program. We hope this joint project will provide additional resource for investigators to cover research costs and contribute their tools to a global scientific community.